Cornerstone Pharmaceuticals Commences Phase I Clinical Trial of CPI-613 for the Treatment of B-Cell Non-Hodgkin Lymphoma

Source: Medical News (via PRIMEZONE) - Category: Pharmaceuticals Source Type: news

Related Links:

Authors: Nagpal SDS, Singh NP, Mishra P, Singh A Abstract Rheumatoid arthritis (RA) is a common rheumatological condition affecting the joints and has a wide range of extra-articular manifestations. A 69 year old male, known case of rheumatoid arthritis presented to our OPD with right lower limb redness and swelling, and left axillary lymph node swelling. Lymph node biopsy revealed a high grade diffuse large B-cell lymphoma with co-expression of c-myc and bcl-2 (double expressor). RA increases the risk of both Hodgkin's lymphoma (HL) and non-Hodgkin's Lymphoma (NHL). The association with diffuse large B-cell lympho...
Source: Journal of the Association of Physicians of India - Category: General Medicine Tags: J Assoc Physicians India Source Type: research
Conditions:   Non-Hodgkin's Lymphoma;   Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma;   Chronic Lymphoblastic Leukemia;   Peripheral T Cell Lymphoma Intervention:   Biological: Autologous γδT cells Sponsors:   Institute of Hematology & Blood Diseases Hospital;   Beijing GD Initiative Cell Therapy Technology Co.,Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The objective of this study was to develop a population-pharmacokinetic model of durvalumab in patients with various hematologic malignancies and to investigate the effects of demographic and disease factors on the pharmacokinetics in this population.MethodsA total of 1812 concentrations from 267 patients with myelodysplastic syndromes, acute myeloid leukemia, multiple myeloma, non-Hodgkin lymphoma, or Hodgkin lymphoma were included in the analysis.ResultsThe pharmacokinetics of durvalumab was adequately described by a two-compartment model with first-order elimination. A decrease in durvalumab clearance over time was main...
Source: Clinical Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research
Authors: Cannavale K, Xu H, Xu L, Sattayapiwat O, Rodriguez R, Bohac C, Page J, Chao C Abstract INTRODUCTION: Anemia is a common adverse effect of myelosuppressive chemotherapy, and the development of chemotherapy-induced anemia (CIA) is more common in patients with hematologic malignant tumors. OBJECTIVE: To assess the incidence and treatment pattern of CIA in patients diagnosed with non-Hodgkin lymphoma (NHL) from a large managed care organization in California. METHODS: Patients diagnosed with NHL between 2010 and 2012 were studied to provide an updated picture of CIA in current hematology-oncology pract...
Source: The Permanente journal - Category: General Medicine Tags: Perm J Source Type: research
Publication date: Available online 17 July 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Fernando Cabanillas, Noridza Rivera, Mirelis Acosta, Wandaly Pardo, Pedro Solivan, Caroline Rivera, Idalia LiboyAbstractBackgroundOur objective was to evaluate the impact of lenalidomide in patients with aggressive lymphoma who attained
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Panniculitis-like T-cell lymphoma is an uncommon type of non-Hodgkin lymphoma, occurring usually in the form of nodules within the subcutaneous fat tissue of the extremities or trunk. In the literature, subcut...
Source: Diagnostic Pathology - Category: Pathology Authors: Tags: Case Report Source Type: research
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research
No optimal salvage therapy for relapsed/refractory aggressive histological types of non-Hodgkin lymphoma exists. We explored a combination of single-agent lenalidomide following gemcitabine, rituximab, oxaliplatin combination ( “GROC-Rev”) in 33 patients. We observed a response rate of 61% (39% complete response rate) and 3-year overall survival of 47%, superior to previous experience. GROC-Rev is a new salvage regimen with encouraging results.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
A novel antibody-drug conjugate (ADC) for adults with refractory or relapsing diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma, has received accelerated FDA approval. Up to 40% of patients with DLBCL will relapse.
Source: JAMA - Category: General Medicine Source Type: research
Abstract Background and objectives: Lymphoma patients experience a psychological and physiological decline that could be reversed by exercise. However, little is known about the effects of the exercise on psychological and physical fitness variables. Therefore, the purpose of this longitudinal study was to assess self-efficacy, fatigue and physical fitness before and after an eight-week exercise intervention. Materials and Methods: Thirty-six participants (54.4 ± 19.1 years) performed a supervised exercise program (~60 min, 2d·wk-1). Each session included a combined progressive training of cardioresp...
Source: Medicina (Kaunas) - Category: Universities & Medical Training Authors: Tags: Medicina (Kaunas) Source Type: research
More News: Clinical Trials | Lymphoma | Non-Hodgkin's Lymphoma | Pharmaceuticals